Here are three points:
1. ProteiOS is composed of minimally manipulated allogenic bone marrow.
2. It contains angiogenic, mitogenic and osteoinductive proteins and the highest amount of non-recombinant BMP-2.
3. The device may be used with the surgeon’s choice of FDA-approved scaffold or matrix.
“In addition to the significant array of growth factors in the product, it has easy storage and prep and offers significant cost and time savings over rhBMP-2 and stem cell products,” said Scott Cadotte, vice president of sales and marketing, Biologica Technologies.
More articles on devices:
FDA approves Mobi-C disc labeling update; includes 5-year study data: 6 things to know
Exactech launches Acapella One Cervical Spacer System: 5 key points
Life Spine releases devices for expandable lateral interbody fusions: 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
